Ms. Susan Bobulsky's most recent trade in Adaptive Biotechnologies Corp was a trade of 6,444 shares done at an average price of $30 . Disclosure was reported to the exchange on Oct. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 06 Oct 2026 | 6,444 | 389,350 (0%) | 0% | 30 | 193,320 | - |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 15 Sep 2026 | 1,195 | 395,794 (0%) | 0% | 27 | 32,265 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 10 Aug 2026 | 3,000 | 396,989 (0%) | 0% | 25 | 75,000 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 24.00 per share. | 30 Jul 2026 | 1,299 | 399,989 (0%) | 0% | 24 | 31,176 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 16 Jul 2026 | 5,000 | 401,288 (0%) | 0% | 23 | 115,000 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 01 Jul 2026 | 487 | 406,288 (0%) | 0% | 22 | 10,714 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 20.50 per share. | 25 Jun 2026 | 5,000 | 406,775 (0%) | 0% | 20.5 | 102,500 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 11 Jun 2026 | 5,000 | 411,775 (0%) | 0% | 19 | 95,000 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 04 Jun 2026 | 11,000 | 416,775 (0%) | 0% | 18 | 198,000 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 13.17 per share. | 11 Mar 2026 | 41,338 | 427,775 (0%) | 0% | 13.2 | 544,421 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 13.17 per share. | 11 Mar 2026 | 41,338 | 427,775 (0%) | 0% | 13.2 | 544,421 | - |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 62,500 | 469,113 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 62,500 | 469,113 (0%) | 0% | 0 | - | |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 59,375 | 406,613 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 59,375 | 406,613 (0%) | 0% | 0 | - | |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | 04 Mar 2025 | 180,029 | 180,029 | - | - | Stock Option (right to buy) | ||
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 119,971 | 373,261 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 119,971 | 373,261 (0%) | 0% | 0 | - | |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 26,023 | 347,238 (0%) | 0% | 7.0 | 181,641 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 26,023 | 347,238 (0%) | 0% | 7.0 | 181,641 | - |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | 08 Oct 2024 | 5,000 | 0 | - | - | Stock Option (right to buy) | ||
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 08 Oct 2024 | 5,000 | 253,290 (0%) | 0% | 2.0 | 9,900 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | 04 Mar 2024 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | ||
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 132,979 | 261,281 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 6,975 | 248,290 (0%) | 0% | 3.4 | 23,994 | Common Stock |
| Adaptive biotech Corp | Ms. Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 6,016 | 255,265 (0%) | 0% | 3.4 | 20,635 | Common Stock |